NTLA: Clinical Hold Resolution Will Reopen ATTR Phase 3 Upside Potential

Analysts have lifted the fair value estimate for Intellia Therapeutics to $26.70 from $25.29. This reflects a series of higher price targets across the Street as recent FDA decisions on the MAGNITUDE program ease regulatory concerns and support more optimistic assumptions on revenue growth, profitability, and long-term P/E potential.

Analyst Commentary

Recent Street research around Intellia Therapeutics clusters around the FDA decision to lift clinical holds on the MAGNITUDE program for nexiguran ziclumeran and related TTR studies. Most firms have adjusted price targets and ratings as they recalibrate risk around the nex-z franchise, MAGNITUDE execution, and the broader biotech backdrop.

Bullish Takeaways

Bullish analysts see the FDA lift of the MAGNITUDE and MAGNITUDE-2 clinical holds as removing a key overhang on the stock, which in their view supports higher fair values tied to the nex-z franchise.
Several positive notes highlight that regulators accepted updated exclusion criteria, protocol amendments, and enhanced liver monitoring, which is seen as improving trial visibility and supporting continued enrollment without further major design disruption.
Some bullish analysts point to a large potential market in transthyretin amyloidosis cardiomyopathy and polyneuropathy, and describe the MAGNITUDE study and related ATTR programs as central to their valuation frameworks for Intellia.
There is also optimistic commentary around upcoming readouts such as hereditary angioedema data and continued ATTR execution, which analysts link to catalysts that could influence longer term revenue and P/E assumptions.

Bearish Takeaways

Bearish analysts remain cautious on safety and tolerability, emphasizing that, even with the clinical hold lifted, careful monitoring is needed given available therapeutic alternatives in ATTR and prior liver toxicity concerns.
Some research flags that market reaction to the regulatory news has been relatively muted, which they interpret as investors still assigning a discount for execution risk and residual safety questions in the MAGNITUDE program.
A few notes reference reductions in price targets or more neutral ratings, reflecting concerns that demand and physician adoption could be influenced by the earlier safety event, even with updated protocols in place.
There is also a more conservative view from some houses that, while the regulatory outcome is positive, the stock already reflects a portion of the nex-z opportunity, leaving less room for error on trial timelines and future data quality.

What's in the News

Intellia has initiated a rolling biologics license application (BLA) to the FDA for lonvo z, an in vivo CRISPR gene editing candidate for hereditary angioedema. The submission is supported by positive topline Phase 3 HAELO data showing the trial met its primary and all key secondary endpoints for a one time outpatient treatment (Key Developments).
The company reported positive topline results from the global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo z) in hereditary angioedema. A one time 50 mg dose reduced attacks by 87% versus placebo over weeks 5 to 28, with a mean monthly attack rate of 0.26 for lonvo z versus 2.10 for placebo (Key Developments).
The FDA has removed clinical holds on the MAGNITUDE and MAGNITUDE 2 Phase 3 trials of nexiguran ziclumeran for transthyretin amyloidosis cardiomyopathy and polyneuropathy, after Intellia and the agency aligned on mitigation steps such as enhanced liver monitoring, steroid use guidance, and revised exclusion criteria (Key Developments).
Intellia completed a follow on equity offering of US$180.0 million, selling 16,744,187 common shares at US$10.75 each, following a previously filed US$150 million offering (Key Developments).
Certain common stock, stock options, and restricted stock units held by Intellia, its directors, and executive officers are subject to a lock up agreement that runs from April 28, 2026 to June 28, 2026. This limits disposals or hedging of these securities without underwriter consent (Key Developments).

Valuation Changes

Fair Value Estimate was raised slightly to $26.70 from $25.29, implying a modest uplift in the intrinsic value assessment for the stock.
The Discount Rate edged down slightly to 7.17% from 7.24%, reflecting a small change in the required return used in the valuation model.
Revenue Growth was updated to 131.01% from 106.26%, indicating a higher assumed growth rate for future dollar revenue.
Net Profit Margin was reset to 2.05% from 12.79%, pointing to a more conservative view on future dollar earnings relative to sales.
Future P/E was raised to a very high 335.65x from 59.11x, signaling a much richer multiple embedded in the long-term earnings valuation.

16 views

Key Takeaways

Accelerated clinical progress and expanding market opportunities position Intellia for earlier commercialization and significant long-term revenue growth.
Improved financial discipline and strong clinical validation support sustainable margins, enhanced payer acceptance, and recurring revenue from commercialization and partnerships.
Competitive pressures, high development costs, pipeline concentration, and reimbursement barriers threaten Intellia's growth, profitability, and ability to sustain its technological edge over time.

Catalysts

About Intellia Therapeutics

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.What are the underlying business or industry changes driving this perspective?

Growing patient and physician enthusiasm for Intellia's lead in vivo CRISPR therapies is driving faster-than-expected enrollment across multiple late-stage clinical trials (including an expanded 1,200-patient ATTR cardiomyopathy study and strong uptake in HAE), positioning the company to achieve meaningful clinical readouts and regulatory milestones ahead of prior guidance-this advances timelines to potential commercialization, driving long-term revenue growth prospects.
The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends-especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE-supporting higher future patient volumes and underpinning potential multi-launch revenue inflection points.
Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.
Strengthening real-world validation of the company's platform-with mature clinical data showing durable, attack-free results in HAE and deep TTR reductions plus positive functional outcomes in ATTR-should bolster pricing power, enhance payer acceptance, and create leverage for value-based reimbursement, directly benefiting gross margins and long-term profitability.
Rapid technological and regulatory advancements in gene-editing-including increased healthcare investments, accelerating review pathways, and support for first-in-class CRISPR therapies-create a favorable environment for Intellia's platform to secure approvals, forge additional partnership/licensing opportunities, and achieve sustainable, recurring non-dilutive revenues through both commercialization and collaborations, increasing top-line growth and earnings potential.

Intellia Therapeutics Earnings and Revenue Growth

Intellia Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Intellia Therapeutics's revenue will grow by 131.0% annually over the next 3 years.
Analysts assume that profit margins will increase from -597.0% today to 2.1% in 3 years time.
Analysts expect earnings to reach $16.7 million (and earnings per share of $0.32) by about May 2029, up from -$394.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.4 billion in earnings, and the most bearish expecting $-542.0 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 336.0x on those 2029 earnings, up from -5.1x today. This future PE is greater than the current PE for the US Biotechs industry at 17.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.17%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Mounting competition from alternative gene therapy and RNAi approaches-including established and newly launched therapies in ATTR amyloidosis and HAE-could limit nex-z and lonvo-z's market share and weaken Intellia's pricing power, impacting long-term revenue growth and gross margins.
Reliance on major late-stage clinical trial results for limited lead programs (nex-z, lonvo-z) creates revenue concentration risk; any regulatory, clinical, or safety setbacks could significantly delay or diminish future earnings and long-term profitability.
High R&D expenses and ongoing cash burn, combined with no near-term commercial product revenues, raise the risk of shareholder dilution or funding constraints, potentially pressuring net margins and earnings despite current cash runway guidance.
Payer scrutiny and reimbursement challenges for costly, potentially one-time gene-editing therapies-especially in crowded indications-could limit uptake, slow commercial ramp, and jeopardize expected revenue streams.
Advances in other gene editing or treatment modalities (such as prime editing, base editing, or more effective RNAi) could erode Intellia's technological lead, making its CRISPR platform less differentiated over the long term, which would negatively affect revenue growth and long-term valuation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $26.7 for Intellia Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $95.0, and the most bearish reporting a price target of just $8.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $814.8 million, earnings will come to $16.7 million, and it would be trading on a PE ratio of 336.0x, assuming you use a discount rate of 7.2%.
Given the current share price of $14.28, the analyst price target of $26.7 is 46.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Intellia Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Paused Trials Will Drive Rebound After Resolution Of Safety Concerns